By salvaging F-actin-associated proteins for XP, the DNGR-1 pathway preferentially primes CD8+ T cells against FABP neoantigens and thereby leads to immunoediting of the antigenic repertoire of cancer cells. The gene discussed is CLEC9A; the disease is cancer.